In vivo alemtuzumab reduces the risk of graft-versus-host disease (GVHD) and non-relapse mortality following reduced intensity allogeneic transplantation. However, it also delays immune reconstitution leading to frequent infections and potential loss of graft-versus-tumor responses. In this trial, we have tested the feasibility of alemtuzumab dose de-escalation in the context of Fludarabine-Melphalan conditioning and HLAidentical sibling transplantation. Alemtuzumab was given within 1-2 days prior to graft infusion and the dose reduced from 60mg to 20mg in four sequential cohorts (total n=106). Pharmacokinetic studies were fitted to a linear, two-compartment model in which dose reduction led to incomplete saturation of CD52 binding sites and greater antibody clearance. Increased elimination was particularly evident in the 20mg group where patients had CD52-expressing tumors at the time of transplantation. The 20mg dose was also associated with a greater risk of severe GVHD (acute grade III-IV or chronic extensive) compared to >20mg (Hazard ratio 6.7, 95% CI [2.5-18.3]). In contrast, dose reduction to 30mg on day -1 was associated with equivalent clinical outcomes to higher doses but better lymphocyte recovery at 12 months. In conclusion, alemtuzumab dose reduction to 30mg is safe in the context of reduced intensity conditioning and HLA-identical sibling transplantation.
Introduction
Reduced intensity conditioning prior to allogeneic hematopoieic stem cell transplantation (HSCT) has considerably broadened the applicability of this approach as therapy for patients with haematological malignancy. This treatment strategy relies upon the graft-versus-tumour (GVT) effect to eradicate persistent cancer. A critical barrier to the success of this approach is the risk of graft-versus-host disease (GVHD), which can affect between 30-70% of patients according to the protocol used and population treated 1 . The development of GVHD contributes to a higher risk of non-relapse mortality (NRM) either directly or indirectly, as a result of infection occurring in individuals requiring intense immunosuppression. Efforts to reduce the risk of GVHD have included incorporation of alemtuzumab into reduced intensity conditioning regimens 2, 3 . Alemtuzumab is a humanised IgG 1 anti-CD52 monoclonal antibody that has broad lymphocyte-depleting properties 4 . When used in vivo prior to graft infusion, it is highly effective in preventing GVHD with reported incidences of 2-21% for acute grade II-IV GVHD and 0-13% for chronic extensive GVHD 2, 3, [5] [6] [7] [8] . This lack of GVHD translates into significant reductions in treatment-related deaths, a benefit that is particularly evident in the unrelated donor setting 2 .
Furthermore, this approach permits the use of subsequent cellular therapies, such as donor leukocyte infusions (DLI) 9 or antigen-specific T cells, otherwise contraindicated in the presence of early GVHD.
We have previously reported the use of alemtuzumab at a fixed total dose of 100mg divided over 5 days (days -8 to -4) in the context of a Fludarabine and Melphalan conditioning protocol 3 . Using this dose regimen, the terminal half-life of the antibody is 8 days and antibody is still detectable at levels sufficient to induce antibody-mediated cellular cytotoxicity (>100ng/ml 10 ) after 2 months following transplantation 11 .
As a consequence, immune reconstitution is markedly delayed and patients have frequent infections [12] [13] [14] .
Slow kinetics of immune reconstitution following reduced intensity conditioning may also lead to high rates of mixed chimerism and negatively impact upon the overall integrity of the GVT response. Delayed adoptive transfer of donor T cells is efficient at correcting mixed chimerism and in certain disorders, at mediating GVT effects 9 . However, the delay in immune recovery may be a significant disadvantage in patients with advanced disease or rapid tumour growth where GVT responses are required early following transplantation.
We reasoned that reductions in the dose of alemtuzumab at the time of transplantation might improve immune reconstitution without increasing the risk of GVHD. We therefore conducted a prospective, multi- 
Patients and methods

Trial design
Patients were recruited from September 2003 to February 2007 at ten UK transplant centers.
The protocol was approved by the UK Multicenter Research Ethics Committee and by individual center Institutional Review Boards. All patients and donors gave written informed consent in accordance with the Declaration of Helsinki. Eligible patients were those with hematological malignancies who due to age, prior therapy or diagnosis, would not normally be offered allogeneic transplantation with ablative conditioning but were suitable for a reduced intensity HSCT. Other inclusion criteria were age 18-65 years, life expectancy > 3 months and possession of at least one HLA identical sibling. Exclusion criteria were creatinine clearance <40ml/min, left ventricular ejection fraction <40%, bilirubin >3x above normal limit, pregnancy or lactating women and serious co-morbidity that would limit lifespan or ability to tolerate chemotherapy. Patient pretransplantation characteristics are detailed in Table 1 .
Conditioning Regimen and alemtuzumab dose de-escalation
Conditioning consisted of Fludarabine 30 mg/m 2 /day from day -7 to day -3, Melphalan 140 mg/m2 on day -2 and alemtuzumab. The dose of alemtuzumab was reduced step-wise in four groups: 60mg (2 x 30mg given i.v. on days -2 and -1); 40mg (2 x 20mg given i.v. on days -2 and -1); 30mg (1 x 30mg given i.v. on day -1); and 20mg (1x 20mg given on day-1). Each cohort was planned to be of 25 patients. Using a type 1 error of 0.05, a group size of 25 would provide a 0.8 probability of detecting an increase in the proportion of patients with acute grade II-IV GVHD from 10% (the expected level using in vivo alemtuzumab) to a clinically significant proportion of 30% (the lower limit of the expected level following HLA-identical sibling transplantations in the absence of alemtuzumab). Recruitment to subsequent cohorts required the Data and Safety Monitoring Committee to review data from the previous cohorts and invoke stopping rules if required. Further accrual within the current cohort was permissible until this had been completed.
All patients were given i.v. methylprednisolone 2mg/kg i.v. at the time of the first alemtuzumab infusion. As per our standard protocol, patients were given ciclosporin (3mg/kg/day IV from day -1), which was tapered from 3 months post-transplant in the absence of GVHD. The preferred donor stem cell source was granulocyte-colony stimulating factor (G-CSF)-mobilised and 
Alemtuzumab levels and pharmacokinetics
Alemtuzumab levels were detemined by ELISA. CD52 fusion protein (obtained from Prof Herman Waldmann, University of Oxford 15 ) was absorbed onto a microtitre plate at a concentration of 2.5 µg/mL, 100 µL/well and the plates were blocked with PBS containing 2% (w/v) BSA. Test samples were applied and incubated for 1 h at 25 o C. The plates were washed and bound alemtuzumab was detected using a monoclonal peroxidase-labelled mouse anti-human IgG 1 followed by tetramethylbenzidine substrate. After stopping the reaction with 5% (v/v) HCl, the absorbance was measured at 450nm with background correction at540 nm. The concentration of test and quality control samples was determined by interpolation on a standard curve using a four parameter logistic model. The detection limit was 37.5ng/ml. 
Study end points
The primary endpoints of the study were the cumulative incidence of acute and chronic GVHD, non-relapse mortality (NRM), the incidence of full donor chimerism and infection.
Pharmacokinetic studies were performed in a subset of patients. Secondary endpoints included overall survival (OS) and progression-free survival (PFS). 
Statistical methods
Results
Patients
A total of 106 patients were recruited to the trial. Median follow up was 2.6 years and minimum follow-up was 14 months. The median age was 50 years (range 17-64 years). Patient pre-transplantation characteristics were similar in each cohort, although there were more patients with advanced disease (defined in the whole cohort as acute leukaemia >CR1, chronic myeloid leukaemia >1 st chronic phase) or prior autologous transplantation in the 60 mg cohort (Table 1) .
Engraftment
The median time for neutrophil engraftment overall was 13 days (>0. 
GVHD
The numbers of patients in each dose cohort developing acute pattern grade II-IV or chronic extensive GVHD before DLI are shown in Tables 2-4 . As shown in Table 3 , there was a significantly higher risk of acute grade II-IV GVHD (Hazard ratio [HR] 16.6, 95% CI 1.8-150), chronic extensive GVHD (HR 4.1, 95% CI 1.4-12.4) and any severe GVHD (acute grade III-IV or chronic extensive, HR 6.7, 95% CI 2.5-18.3) in the 20mg group compared to the >20mg cohort. In contrast, HR comparisons for GVHD between the 30mg and >30mg group showed no significant differences ( Figure 1A , p<0.001). In contrast, the 1-year cumulative incidences of severe GVHD were similar in the 30mg group compared to the >30mg groups (6%, 95% CI 0-25% versus 14%, 95% CI 5-27%, Figure 1C , p=NS). In total, 5 patients died of complications relating to GVHD (n=1 in 60mg group, n=1 in 40mg group and n=3 in 20mg group).
Forty-three patients received DLI for mixed chimerism (n=30) or persistent/relapsed disease (n=13). The number of patients developing either acute pattern grade III-IV or chronic extensive GVHD following DLI For personal use only. on October 24, 2017. by guest www.bloodjournal.org From was 7 in total (16%) and there were no significant differences between the groups (60mg, 3/13; 40mg, 0/9; 30mg, 1/11; and 20mg, 3/10).
Non-relapse mortality
Competing risk estimates for cumulative incidences of day 100, 1-year and 2-year NRM are shown in Tables 2 and 3 . The major causes of death were infection (n=9) or infection complicating GVHD (n=5).
Other causes of death included respiratory failure (n=2), ciclosporin toxicity (n=1), intracranial haemorrhage (n=1) and secondary cancer (n=1). Overall, day 100, 1-year and 2-year estimates of NRM were 5% (95% CI, 2-10%), 12% (95% CI, 7-19%) and 17% (95% CI, 10-24%) respectively. As shown in Tables 2-4 and Figures 1C-D , no differences were evident in the cumulative incidences of NRM between the individual groups (Table 2) or in comparisons between the 20mg and >20mg (Table 3, Figure 1B ) or 30mg and >30mg groups (Table 4, Figure 1D ).
Overall survival and progression-free survival
Overall, Kaplan-Meier estimates of 2-year overall survival and progression-free survival were 72% (95% CI, 63-80%) and 59% (95% CI, 48-68%), respectively. As shown in Tables 2-4, no differences were evident between the groups.
Chimerism and immune reconstitution
Chimerism data were available for 87 of 99 evaluable patients (Table 2-4). Overall, initial chimerism at 3 months was full donor in 34 patients (39%), mixed in 52 patients and autologous in one patient. No differences were evident between the groups. Upon withdrawal of immunosuppression or subsequent DLI, the proportion of patients attaining full donor chimerism at 2 years increased to 75% overall, again with no differences between the individual groups.
The median number of infections per patient was two (IQR 1, 4) and the number did not differ between the groups (Tables 2-4 ). There were no differences in the number of patients dying as a result of infection (data not shown). The proportion of CMV sero-positive patients developing CMV reactivation were also similar in each group and there were no differences in the incidence of CMV disease (Tables 2-4 ).
Although no differences were evident in the risk of infections, we also examined the recovery of lymphocytes at 1, 3, 6 and 12 months post-transplantation. In this evaluation, patients receiving protocol DLI for mixed chimerism within the first 12 months were included (60mg, n=7, median DLI dose 4 x 10 6 CD3+ cells/kg recipient weight; 40mg, n=5, median dose 3 x 10 6 CD3+/kg; 30mg, n=7, median dose 4 x 10 6 CD3+/kg; and 20mg, n=9, median dose 1 x 10 6 CD3+/kg), whereas patients with relapsed or progressive disease were excluded. No differences in the timing of DLI initiation were observed between the groups (60mg, median 229 days, range 183-245; 40mg, median 239 days, range 223-301; 30mg, median 234 days, range 205-317; and 20mg, median 231 days, range 173-313). As shown in Table 4 , absolute lymphocyte numbers at 12 months in evaluable patients were greater in the 30mg compared to the >30mg cohort, with over 75% of patients in the former group having counts greater than the lower limit of the normal range (number of evaluable patients 30mg, n=20 and >30mg, n=30). In contrast, in the >30mg group, lymphocyte recovery was relatively delayed with >50% of patients having sub-normal lymphocyte counts.
Pharmacokinetics
At a number of centers, blood samples were taken before transplantation, during conditioning and up to 28 days following transplantation (day -3, +0, +7 and +28, n=5-6 each group, Figure 2A ). Following completion of the trial, we determined alemtuzumab concentrations by ELISA (lower limit of detection 37.5mg/l). Although there was wide inter-individual variation within each group, there were significant differences in peak concentrations measured in the 60mg group compared to the lower dose groups ( Figure 2B ). Peak serum concentrations in the 40mg cohort overlapped considerably with the 20 and 30mg cohorts. By day 28, alemtuzumab levels had fallen in all groups, but especially in patients receiving 20 and 30mg doses, where 2 of 5 patients in the 30mg group and 3 of 5 patients in the 20mg group had levels <100ng/ml ( Figure 2B ). Pharmacokinetic data were analysed using NONMEM mixed-effects modelling and choice between individual models made by data adequacy and a goodness-of-fit evaluation. In this sample, a linear two-compartment model was most suitable for describing alemtuzumab concentrations and we used this to estimate clearance (Cl), central volume of distribution One implication of this finding was that patients with CD52-expressing tumors at the time of transplantation might demonstrate more rapid clearance of antibody, especially at low dose. In order to test this, we categorised 49 patients, where peak alemtuzumab levels were available, according to status at transplantation and predicted tumor expression of CD52 17 .
As shown in Figure 3A , peak alemtuzumab levels were broadly similar in patients with and without CD52-expressing tumors at the time of transplantation in the 30, 40 and 60mg groups. However, in 20mg cohort, presence of CD52+ tumour at the time of transplantation was associated with significantly lower peak concentrations. In Figure 3B , As shown in Figure 3A , there was substantial variation in peak concentrations within each dose group and significant overlap between the three lower dose groups. To test whether peak concentrations would be predictive of outcome, we performed a post-hoc analysis of outcomes for patients where peak levels were below or at and above the median value (4177ng/ml). No differences between baseline variables were present between the two groups (data not shown). Using this approach, no differences in GVHD 
Discussion
In this multi-center, prospective trial, we have demonstrated the feasibility of substantial reductions in the dose of in vivo alemtuzumab in the setting of Fludarabine-Melphalan conditioning for HLA-identical sibling transplantations. Dose reductions to 30mg, given at day -1, were compatible with a low risk of GVHD, no increase in NRM and improved lymphocyte recovery at 1 year. In contrast, further dose reduction to 20mg led to higher rates of severe GVHD and peak antibody levels were more likely to be influenced by the presence of CD52+ tumor at the time of transplantation.
One recent observational study has also reported the potential feasibility of reducing in vivo alemtuzumab dosing prior to reduced intensity allogeneic stem cell transplantation. Bertz et al.
employed a similar time schedule to our study for alemtuzumab dose de-escalation (day-2 and-1) in their reported experience of unrelated and related donor transplantations using a variety of fludarabine-based protocols 18 . In their report, reducing the dose to 10-20mg on day -1 was associated with cumulative incidences of acute grade II-IV GVHD of 10-16% following sibling and 28-34% following unrelated donor transplantations. The incidences of chronic extensive GVHD in these groups were 14-17% overall. They concluded that the optimal alemtuzumab dose was between 10-20mg on day-1, irrespective of the donor type. This is a lower dose than our results would suggest is feasible if the risk of severe GVHD is to stay relatively low, with our optimal dose being 30mg on day -1. One potential caveat to their findings is that the majority of patients in their series were treated for myeloid malignancies that lack expression of CD52 and only 4% of patients in the lowest dose cohort had a lymphoproliferative disorder. Thus, it is possible that rates of alemtuzumab clearance differed substantially from our trial where a greater proportion of trial participants had CD52-expressing indolent lymphoproliferative disorders. Accordingly, we would recommend that substantial alemtuzumab dose reductions in unrelated donor patients should preferably take place in the context of a prospective study where issues such as the effect of diagnosis or the degree of mismatch can be addressed in more detail.
A linear, two-compartment model was adequate to describe the pharmacokinetic data in this study, similar to those reported for other monoclonal antibodies [19] [20] [21] . At the highest dose, V 1 values (central distribution) corresponded to those reported for other antibodies that are largely Although lymphocyte recovery at 12 months was more rapid in the 30mg group than the higher dose cohorts, early lymphocyte recovery, the rate of infections and the incidence of full donor chimerism were similar in all groups. Thus, we identified no optimal dose that enabled dramatic improvements in immune reconstitution without inducing GVHD. This implies that efforts to bolster early immune reconstitution with the strategy of in vivo T cell depletion at the time of transplantation will continue to require add-back of therapeutic T cells in the post-transplantation period. For example, we and others, have demonstrated the potential of transferring antigenspecific T cells as a pre-emptive or prophylactic strategy to accelerate anti-CMV immune reconstitution [26] [27] [28] . This strategy is being extended to other pathogens including EBV, adenovirus and Aspergillus 29, 30 . Transfer of unselected DLI using an escalated dose regimen can correct mixed chimerism or eradicate persistent disease, with only a low risk of GVHD in the HLAidentical setting 9 . In this study, nearly half of the patients received DLI and significant GVHD was only observed in 16% of patients overall, emphasizing the general applicability of this approach, despite substantial reductions in alemtuzumab dose. Other approaches such as CD8 depletion of DLI may also be of value in reducing the risk still further especially in patients where the intention is to correct mixed chimerism 31, 32 .
In conclusion, this prospective study has demonstrated that a substantial dose reduction of alemtuzumab to 30mg (given on day-1 as a single infusion) is possible in the context of reduced intensity conditioned HLA-identical sibling transplantations without increasing NRM or the incidence of GVHD while improving immune reconstitution in terms of lymphocyte numbers. In future UK collaborative studies involving HLA-identical sibling transplantations, we therefore intend to adopt the dose of 30mg as standard. While this trial was not primarily designed to evaluate differences in PFS, an important question for future studies involving a less heterogenous group of patients will be whether de-escalation of the alemtuzumab dose will improve initial disease control and reduce the risk of relapse. For personal use only. on October 24, 2017. by guest www.bloodjournal.org From
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